Neovacs (ALNEV)

Currency in EUR
1.1948
+0.5148(+75.71%)
Real-time Data·
Unusual trading volume
ALNEV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.19481.3000
52 wk Range
0.68009,879.0000
Key Statistics
Prev. Close
0.68
Open
1.2
Day's Range
1.1948-1.3
52 wk Range
0.68-9,879
Volume
70.68K
Average Volume (3m)
6K
1-Year Change
-99.9859%
Book Value / Share
944,484.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALNEV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low Price / Book multiple

Neovacs News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Earnings

Latest Release
Nov 21, 2025
EPS / Forecast
-5.11 / --
Revenue / Forecast
157.72K / --
EPS Revisions
Last 90 days

ALNEV Income Statement

Compare ALNEV to Peers and Sector

Metrics to compare
ALNEV
Peers
Sector
Relationship
P/E Ratio
−0.1x−2.7x−0.4x
PEG Ratio
-−0.070.00
Price/Book
0.0x1.0x2.6x
Price / LTM Sales
1.2x15.9x3.0x
Upside (Analyst Target)
-128.8%50.7%
Fair Value Upside
Unlock6.7%7.2%Unlock

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNa Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of asthma, dermatomyositis, and all food allergies; and kinoid vaccine that simultaneously targets IL-4 and IL-13 allergies. The company was founded in 1993 and is based in Suresnes, France.

People Also Watch

4.195
ALMDT
+2.57%
0.0108
ALTAO
-5.26%
114.70
ABVX
+4.08%
7.935
MAUP
-0.19%
0.2840
ALSEN
-0.18%

FAQ

What Is the Neovacs (ALNEV) Stock Price Today?

The Neovacs stock price today is 1.1948 EUR.

What Stock Exchange Does Neovacs Trade On?

Neovacs is listed and trades on the Paris Stock Exchange.

What Is the Stock Symbol for Neovacs?

The stock symbol for Neovacs is "ALNEV."

What Is the Neovacs Market Cap?

As of today, Neovacs market cap is 190.0500K EUR.

From a Technical Analysis Perspective, Is ALNEV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Neovacs Stock Split?

Neovacs has split 8 times.

How Many Employees Does Neovacs Have?

Neovacs has 16 employees.

What is the current trading status of Neovacs (ALNEV)?

As of Aug 07, 2026, Neovacs (ALNEV) is trading at a price of 1.1948 EUR, with a previous close of 0.6800 EUR. The stock has fluctuated within a day range of 1.1948 EUR to 1.3000 EUR, while its 52-week range spans from 0.6800 EUR to 9,879.0000 EUR.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.